The obesity medicine specialist told a Fall Clinical 2026 panel that sleep apnea, MASH and heart coverage can open GLP-1 access, and that retatrutide could reach market next year.
Recap by typeshit. Full story at Dermatology Times.
The weight loss drug class started with a lizard. A short local feature looks at how the Gila monster led researchers to GLP-1 medicines.
Healio
At the Cardiometabolic Health Congress, the UAB professor asked whether maximal weight loss is optimal and flagged that most non-diabetic patients quit GLP-1s within two years.
A short item claims a newer group of weight loss drugs beats Ozempic, without naming the drugs or the data behind the claim.
The digital health doctor shares a take on GLP-1 therapy paired with lifestyle change and digital programs, calling the finding unsurprising.
Hotels are adding fridges for medication, protein-heavy menus and wellness-focused itineraries as more guests travel while on GLP-1 drugs.
Labiotech walks through Novo Nordisk's 2026 pipeline and the new target it has set for risk-adjusted sales from drugs still in development.
Loading…